Miami CardioMetabolic Summit Evaluation

Please score your agreement with or assessment of the following questions and statements by rating on a scale of 1 to 5, with 5 representing the highest level of satisfaction or agreement. *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	Not Applicable
The information and/or skills learned will enhance my professional competence or ability.	The information and/or skills learned will enhance my professional competence or ability. - 5	The information and/or skills learned will enhance my professional competence or ability. - 4	The information and/or skills learned will enhance my professional competence or ability. - 3	The information and/or skills learned will enhance my professional competence or ability. - 2	The information and/or skills learned will enhance my professional competence or ability. - 1	The information and/or skills learned will enhance my professional competence or ability. - Not Applicable
This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients.	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 5	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 4	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 3	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 2	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - 1	This activity conveyed information which will assist me in improving the health and/or treatment outcomes of of my patients. - Not Applicable

As a result of participating in this course, to what extent do you agree that you will be better able to accomplish these objectives *

Scoring Key: 5=Strongly Agree 4=Agree 3=Neutral 2=Disagree 1=Strongly Disagree 0=Not applicable to my practice

	5	4	3	2	1	Not Applicable
Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence.	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - 5	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - 4	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - 3	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - 2	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - 1	Address the persistent sex-specific gaps found in guidelines, recommendations and prevention of cardiovascular disease strategies for women, and recognize diagnostic and therapeutic adherence. - Not Applicable
Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients.	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - 5	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - 4	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - 3	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - 2	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - 1	Recognize the risk factors associated with asymptomatic carotid atherosclerotic disease, and examine the evidence that supports a conservative approach to carotid revascularization in asymptomatic patients. - Not Applicable
Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke.	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - 5	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - 4	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - 3	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - 2	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - 1	Interpret and implement current guidelines on utilization of cholesterol lowering therapy to reduce the risk of heart attack and stroke. - Not Applicable
Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia.	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - 5	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - 4	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - 3	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - 2	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - 1	Examine and implement the National Lipid Association recommendations for patient-centered management of dyslipidemia. - Not Applicable
Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - 5	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - 4	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - 3	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - 2	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - 1	Cite the clinical trial evidence supporting the use of omega-3 fatty acids in cardiovascular disease prevention - Not Applicable
Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides.	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - 5	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - 4	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - 3	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - 2	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - 1	Review the randomized clinical trials currently evaluating the incremental benefit of adding omega-3 fatty acids to statin therapy in high-risk patients with elevated triglycerides. - Not Applicable
Examine the evidence that reveals how meditation promotes health and well-being.	Examine the evidence that reveals how meditation promotes health and well-being. - 5	Examine the evidence that reveals how meditation promotes health and well-being. - 4	Examine the evidence that reveals how meditation promotes health and well-being. - 3	Examine the evidence that reveals how meditation promotes health and well-being. - 2	Examine the evidence that reveals how meditation promotes health and well-being. - 1	Examine the evidence that reveals how meditation promotes health and well-being. - Not Applicable
Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies.	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - 5	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - 4	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - 3	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - 2	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - 1	Implement strategies to effectively motivate smoking cessation behaviors in patients, and examine pharmacologic options for smoking cessation therapies. - Not Applicable
Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician.	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - 5	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - 4	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - 3	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - 2	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - 1	Implement practical treatment protocols for the management of obesity from the point of view of the practicing physician. - Not Applicable
Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases.	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - 5	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - 4	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - 3	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - 2	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - 1	Explain the role of bariatric surgery and its impact in obese individuals diagnosed with diabetes and cardiovascular diseases. - Not Applicable
Initiate effective patient education discussions about the minimal level of exercise needed for improved health.	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - 5	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - 4	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - 3	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - 2	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - 1	Initiate effective patient education discussions about the minimal level of exercise needed for improved health. - Not Applicable
Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets.	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - 5	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - 4	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - 3	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - 2	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - 1	Recognize components of the optimal diet for cardiovascular health, and explain the scientific evidence behind popular weight loss diets. - Not Applicable
Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals.	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - 5	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - 4	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - 3	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - 2	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - 1	Recognize the key differences and controversies among the multitude of hypertension practice guidelines, and discuss the different rationales for variable BP goals. - Not Applicable
Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone.	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - 5	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - 4	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - 3	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - 2	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - 1	Examine the formal evidence from the FOURIER trial, and explain how targeted treatment at PCSK9 inhibition confers additional cardiovascular benefits beyond lipid-lowering treatment alone. - Not Applicable
Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes.	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - 5	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - 4	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - 3	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - 2	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - 1	Examine the current results of the CANTOS study and explain how targeting inflammation produces a direct benefit on patient outcomes. - Not Applicable
Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events.	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - 5	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - 4	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - 3	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - 2	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - 1	Examine the impact of adding empagliflozin to standard care of type 2 diabetes patients who are at high risk for cardiovascular events. - Not Applicable
Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not.	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - 5	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - 4	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - 3	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - 2	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - 1	Evaluate the implications of the absence of coronary artery calcium (CAC) in reclassifying patients from a risk stratum in which statins are recommended to one in which they are not. - Not Applicable
Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy.	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - 5	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - 4	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - 3	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - 2	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - 1	Examine statin-associated muscular adverse events, and explain how such events are typically temporal due to the initiation of statin therapy. - Not Applicable
Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease.	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - 5	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - 4	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - 3	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - 2	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - 1	Describe and recognize the usefulness of stress testing in patients with suspected coronary artery disease. - Not Applicable
Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain.	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - 5	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - 4	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - 3	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - 2	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - 1	Examine the role of coronary computed tomographic angiography as a diagnostic tool in the evaluation of patients with chest pain. - Not Applicable
Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat.	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - 5	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - 4	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - 3	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - 2	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - 1	Recognize the strong association atrial fibrillation has with other cardiovascular diseases in order to properly manage, diagnose and treat. - Not Applicable
Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options.	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - 5	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - 4	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - 3	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - 2	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - 1	Examine prevention, reversal and treatment strategies for heart failure, considering medical and surgical options. - Not Applicable
Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death.	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - 5	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - 4	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - 3	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - 2	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - 1	Assess the long-term vital prognosis of patients with abdominal aortic aneurysmal disease or peripheral artery disease to determine possible differences in survival, prognostic risk profiles and causes of death. - Not Applicable
Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available.	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - 5	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - 4	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - 3	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - 2	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - 1	Examine the primary causes of aortic stenosis, its progression and risks, and recognize the diagnostic tests and treatment options available. - Not Applicable

How effective were the following speakers in meeting the learning objectives?

Scoring key: 5=Very effective, 4= Effective, 3= Somewhat effective, 2= Slightly effective, 1= Completely Ineffective, N/A= Not Applicable

Thursday *

	5	4	3	2	1	Not Applicable
Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D.	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - 5	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - 4	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - 3	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - 2	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - 1	Keynote Address - Improving the Cardiovascular Health of Women - Martha Gulati, M.D. - Not Applicable

Friday *

	5	4	3	2	1	Not Applicable
Asymptomatic Carotid Stenosis - Barry Katzen, M.D.	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - 5	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - 4	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - 3	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - 2	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - 1	Asymptomatic Carotid Stenosis - Barry Katzen, M.D. - Not Applicable
Cholesterol Management - Paul E. Ziajka, M.D., Ph.D.	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - 5	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - 4	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - 3	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - 2	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - 1	Cholesterol Management - Paul E. Ziajka, M.D., Ph.D. - Not Applicable
Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D.	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - 5	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - 4	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - 3	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - 2	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - 1	Omega 3 Fatty Acids and Cardiometabolic Health - Michael Ozner , M.D. - Not Applicable
Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D.	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - 5	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - 4	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - 3	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - 2	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - 1	Meditation for Health and Well-being: Does It Really Work? - Amishi P. Jha, Ph.D. - Not Applicable
Smoking Cessation - Michael Hernandez, M.D.	Smoking Cessation - Michael Hernandez, M.D. - 5	Smoking Cessation - Michael Hernandez, M.D. - 4	Smoking Cessation - Michael Hernandez, M.D. - 3	Smoking Cessation - Michael Hernandez, M.D. - 2	Smoking Cessation - Michael Hernandez, M.D. - 1	Smoking Cessation - Michael Hernandez, M.D. - Not Applicable
Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D.	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - 5	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - 4	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - 3	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - 2	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - 1	Obesity: Beyond Lifestyle and Bariatric Surgery - Theodore Feldman, M.D. - Not Applicable
Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D.	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - 5	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - 4	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - 3	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - 2	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - 1	Exercise Prescription for Primary and Secondary Prevention - Michael J. Blaha, M.D. - Not Applicable
Best Diet for CVD Prevention - Arthur Agatston, M.D.	Best Diet for CVD Prevention - Arthur Agatston, M.D. - 5	Best Diet for CVD Prevention - Arthur Agatston, M.D. - 4	Best Diet for CVD Prevention - Arthur Agatston, M.D. - 3	Best Diet for CVD Prevention - Arthur Agatston, M.D. - 2	Best Diet for CVD Prevention - Arthur Agatston, M.D. - 1	Best Diet for CVD Prevention - Arthur Agatston, M.D. - Not Applicable
Hypertension Guidelines - Roger Blumenthal, M.D.	Hypertension Guidelines - Roger Blumenthal, M.D. - 5	Hypertension Guidelines - Roger Blumenthal, M.D. - 4	Hypertension Guidelines - Roger Blumenthal, M.D. - 3	Hypertension Guidelines - Roger Blumenthal, M.D. - 2	Hypertension Guidelines - Roger Blumenthal, M.D. - 1	Hypertension Guidelines - Roger Blumenthal, M.D. - Not Applicable
FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D.	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - 5	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - 4	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - 3	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - 2	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - 1	FOURIER: Extensive Lipid Lowering (PCSK9) - Paul E. Ziajka, M.D. - Not Applicable
CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D.	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - 5	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - 4	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - 3	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - 2	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - 1	CANTOS: Residual Inflammation - Christie M. Ballantyne, M.D. - Not Applicable
EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D.	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - 5	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - 4	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - 3	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - 2	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - 1	EMPA REG: New Anti-Diabetic Agent to Lower Cardiovascular Events - Theodore Feldman, M.D. - Not Applicable

Saturday *

	5	4	3	2	1	Not Applicable
Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D.	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - 5	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - 4	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - 3	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - 2	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - 1	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Protagonist: Michael J. Blaha, M.D. - Not Applicable
Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D.	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - 5	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - 4	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - 3	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - 2	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - 1	Statin Therapy in Primary Prevention: Should I Consider CAC Testing? - Antagonist: Khurram Nasir, M.D. - Not Applicable
Heart Failure - Francisco Javier Jimenez, M.D.	Heart Failure - Francisco Javier Jimenez, M.D. - 5	Heart Failure - Francisco Javier Jimenez, M.D. - 4	Heart Failure - Francisco Javier Jimenez, M.D. - 3	Heart Failure - Francisco Javier Jimenez, M.D. - 2	Heart Failure - Francisco Javier Jimenez, M.D. - 1	Heart Failure - Francisco Javier Jimenez, M.D. - Not Applicable
Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D.	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - 5	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - 4	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - 3	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - 2	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - 1	Should I Consider Utilizing a Stress Test for Chest Pain? - David Wolinsky, M.D. - Not Applicable
Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D.	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - 5	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - 4	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - 3	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - 2	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - 1	Should I Consider Utilizing Coronary CTA for Chest Pain? - Ricardo C. Cury, M.D. - Not Applicable
Atrial Fibrillation - Robert S. Fishel, M.D.	Atrial Fibrillation - Robert S. Fishel, M.D. - 5	Atrial Fibrillation - Robert S. Fishel, M.D. - 4	Atrial Fibrillation - Robert S. Fishel, M.D. - 3	Atrial Fibrillation - Robert S. Fishel, M.D. - 2	Atrial Fibrillation - Robert S. Fishel, M.D. - 1	Atrial Fibrillation - Robert S. Fishel, M.D. - Not Applicable
Muscle Ache With Statins - Michael J. Blaha, M.D.	Muscle Ache With Statins - Michael J. Blaha, M.D. - 5	Muscle Ache With Statins - Michael J. Blaha, M.D. - 4	Muscle Ache With Statins - Michael J. Blaha, M.D. - 3	Muscle Ache With Statins - Michael J. Blaha, M.D. - 2	Muscle Ache With Statins - Michael J. Blaha, M.D. - 1	Muscle Ache With Statins - Michael J. Blaha, M.D. - Not Applicable
Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D.	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - 5	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - 4	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - 3	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - 2	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - 1	Peripheral Vascular Disease - Ian Del Conde Pozzi, M.D. - Not Applicable
Aortic Stenosis - Ramon Quesada, M.D.	Aortic Stenosis - Ramon Quesada, M.D. - 5	Aortic Stenosis - Ramon Quesada, M.D. - 4	Aortic Stenosis - Ramon Quesada, M.D. - 3	Aortic Stenosis - Ramon Quesada, M.D. - 2	Aortic Stenosis - Ramon Quesada, M.D. - 1	Aortic Stenosis - Ramon Quesada, M.D. - Not Applicable

Was this course fair, balanced and without commercial bias? *

Yes

Participation in this learning activity has: *

	Yes	No	Not Applicable
Increased my knowledge	Increased my knowledge - Yes	Increased my knowledge - No	Increased my knowledge - Not Applicable
Enhanced my performance	Enhanced my performance - Yes	Enhanced my performance - No	Enhanced my performance - Not Applicable
Improved my competence	Improved my competence - Yes	Improved my competence - No	Improved my competence - Not Applicable
Ensured that my patients will have improved outcomes	Ensured that my patients will have improved outcomes - Yes	Ensured that my patients will have improved outcomes - No	Ensured that my patients will have improved outcomes - Not Applicable

How many patients will you see in your practice who will likely be impacted by what you learned at this activity? *

1-5

6-10

Over 10

Not applicable to my practice

How did you hear about us? *

Would you attend this symposium again next year? *

Yes

If you checked "No,” please tell us why: *

If you checked "No,” please explain why you would not recommend this course: *

Please list specific changes you intend to implement in your daily practice as a result of attending this activity. *

If you do not plan to implement any new strategies learned, please list any barriers or obstacles that might keep you from doing so.

Suggested topics and/or speakers you would like for future symposiums.

Comments

Name

Leave this field blank

You are here

Miami CardioMetabolic Summit Evaluation